New hope for Tough-to-Treat colorectal cancer: experimental combo enters Late-Stage trial

NCT ID NCT07361003

Recruiting now Disease control Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding the experimental drug suvemcitug to standard chemotherapy (trifluridine/tipiracil) helps people with metastatic colorectal cancer that no longer responds to other treatments live longer. About 464 participants will receive either the combination or a placebo plus chemo. The study first checks safety, then measures overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: suvemcitug (an anti-VEGF drug) plus trifluridine/tipiracil chemotherapy tablets
What this could lead to: If it works, this combination could offer a new treatment option that helps people with advanced colorectal cancer live longer after other treatments have failed.
What could go wrong: This is still being tested, and the added benefit of suvemcitug is unproven. Side effects from the combination could be worse than chemo alone, and the trial may not show a survival improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China
Harbin Medical University University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China
The First Affiliated Hospital of Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China
Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.